PDCD1 and neoplasm: In the WH CAF high-level with anti-PD-1 group, the effect of PD-1 monotherapy was comparable to that in the WH CAF high-level group (p = 0.4448, η2 = 0.05951); in contrast, tumor volume control was significant in the combination with erdafitinib group (p = 0.0041, η2 = 0.5772) (Figure 4D).